Xiao-I vs Exascale Labs
AIXI and XLAB side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIXI and XLAB compare
Exascale Labs grew revenue faster over the last twelve months (111% versus −82.5% for Xiao-I).
Exascale Labs keeps more of each dollar of sales as profit, with a net margin of −82.1% compared with −821% at Xiao-I.
Exascale Labs scores higher on the StockData Score (7 against 0 for Xiao-I), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIXI | XLAB |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.4K |
| Share price | $1.78 | $2.27 |
| Change, 1 year | −98.5% | −77.5% |
| Beta (5Y) | 5.54 | −0.38 |
| Employees | 58 | 12 |
| StockData Score | ||
| Total score | 0 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.0× |
| Growth | ||
| Revenue growth (TTM) | −82.5% | 111% (better) |
| Revenue growth, 5Y average | −2.3% | – |
| Profitability | ||
| Gross margin | 44.4% (better) | 16.3% |
| Operating margin | −784% | −32.4% (better) |
| Net margin | −821% | −82.1% (better) |
| FCF margin | −30.3% | – |
| Financial health | ||
| Interest coverage | −213.3× | – |
| Current ratio | 0.06 | 0.20 (better) |
| Altman Z-score | – | −9.96 |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | – |
| Held by insiders | 0.00% | 7.7% |
Go deeper
- AIXI stock overview
- AIXI income statement
- AIXI valuation and score
- XLAB stock overview
- XLAB income statement
- XLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.